|
Subsequent treatments and outcomes in bacillus Calmette-Guerin–unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world data analysis. |
| |
|
Employment - Flatiron Health; Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Flatiron Health; Johnson & Johnson/Janssen; Roche Pharma AG |
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson; Madrigal Pharmaceuticals |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Abbvie; Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - GlaxoSmithKline; Johnson & Johnson; Sanofi |
Travel, Accommodations, Expenses - Janssen Research & Development |
| |
|
Employment - Aura Biosciences; Janssen Research & Development |
Leadership - Aura Biosciences; Janssen Research & Development |
Stock and Other Ownership Interests - Aura Biosciences; Johnson & Johnson |
Honoraria - Wellster Healthtech Group |
Consulting or Advisory Role - Wellster Healthtech Group |
Patents, Royalties, Other Intellectual Property - Founder of Vitruvo eHealth and Developer of a Digital Medicine Application |
| |
|
No Relationships to Disclose |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
Patents, Royalties, Other Intellectual Property - FGFR Tyrosine Kinase Inhibitors For the Treatment Of Advanced Solid Tumors |